Science
Moderator: SABCS Co-director Kent Osborne, MD, director of the Dan L Duncan Cancer Center at Baylor College of Medicine T-DM1 Improved Overall Survival for Heavily Pretreated Patients With HER2-positive Breast Cancer; Phase III BELLE-2 Trial Meets Primary Endpoint of Progression-free Survival; No Significant Difference in Recurrence Rates Among Women With DCIS Taking Anastrozole or Tamoxifen; and DCIS Patients Receiving Anastrozole Reported Symptoms Different From Those Receiving Tamoxifen.